ID Analysts

Our seasoned team of analysts continually monitors investment opportunities around the world, to provide investors with the widest possible array of money-making ideas.

Analyst Articles

Sell to close the Gilead Sciences (GILD) May 72.50 call option, at the market. Stocks are under a bit of pressure this morning and our indicators suggest the market will have to digest even more selling in the near term. We therefore want to lock in our healthy gain… Read More

Stocks are set to close out the year on an up note, a theme that has been echoed repeatedly throughout 2013 with shares up 32 percent on the S&P 500. There’s good reason to celebrate, with the economy improving, plenty of slack to absorb even faster growth and consumer confidence… Read More

We have a nice profit on our Gilead Sciences (GILD) May 72.50 call option. The stock has paused in the $75 area after rebounding, but we expect further gains in the next few weeks. Hold on to your position. Gold is once more probing its former lows in very light… Read More

We are selling one third of our Idenix Pharmaceuticals (IDIX) position. IDIX will now be approximately 8 percent of our portfolio. On December 18, we took an aggressive stance and purchased additional shares of Idenix Pharmaceuticals (IDIX). The move has paid off as the stock rallied… Read More